Corbus Pharmaceuticals Starts Phase 1 Study for CRB-913
Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) has recently announced a significant advance in their clinical trials. The company has initiated the multiple ascending dose (MAD) portion of the Phase 1 study focusing on CRB-913, a novel treatment designed to combat obesity. This comes after the successful analysis of the single ascending dose (SAD) segment launched earlier.
Overview of the Phase 1 Trial
The MAD trial, which is set to be completed in the near future, aims to evaluate the safety and pharmacokinetics of CRB-913 when administered once daily for a week to healthy participants. The results from the earlier SAD study have laid a solid foundation for this next phase, indicating a promising outcome as the research progresses.
Key Findings from Initial Trials
Yuval Cohen, the CEO of Corbus, expressed optimism regarding the data collected thus far, stating that it shows a reassuring transition from preclinical to clinical settings. Notably, there have been no treatment-related neuropsychiatric events, even at higher doses than what initial models estimated would be necessary for efficacy.
Future Directions and Expectations
As the Company gears up for further investigations, they expect to transition to a Phase 1b dose-range finding study aimed at obese individuals later this year. This following study is expected to deepen the understanding of CRB-913’s efficacy. The overall timeline for completing the multiple ascending dose and subsequent studies is projected into a partnership with the upcoming quarters.
Understanding CRB-913 and Its Mechanism
CRB-913 works as an oral small molecule inverse agonist targeting the CB1 receptor, a hallmark mechanism historically linked to weight management. Unlike its predecessors which faced scrutiny over neuropsychiatric risks, CRB-913 is distinguished by its peripherally restricted design, aimed at reducing potential adverse effects while remaining effective.
The Commitment of Corbus Pharmaceuticals
Corbus is dedicated to innovating within the realms of oncology and obesity, utilizing well-known biological pathways to develop meaningful treatments. Their pipeline includes significant candidates such as CRB-701 and CRB-601, showcasing a broader commitment to tackling serious health issues as they emerge.
Collaborative Efforts and Recognized Goals
Part of the Company’s mission includes collaboration with clinical experts to refine their product offerings. The intention is to ensure that treatments like CRB-913 can provide substantial help to those struggling with obesity, paving the way for healthier futures.
Frequently Asked Questions
What is CRB-913?
CRB-913 is an oral small molecule designed as a CB1 inverse agonist aimed at treating obesity by minimizing neurological side effects.
What are the goals of the Phase 1 trial?
The Phase 1 trial aims to assess the safety, tolerability, and pharmacokinetics of CRB-913 in healthy volunteers before testing in obese individuals.
When will the results of the MAD portion be available?
Results from the MAD phase are anticipated as the trial is expected to complete soon, paving the way for further studies.
How does CRB-913 differ from other obesity treatments?
CRB-913 is designed to have reduced brain penetration, addressing concerns associated with previous drug classes that had neuropsychiatric risks.
Who can I contact for more information?
For inquiries, you can reach Sean Moran, the Chief Financial Officer of Corbus Pharmaceuticals via email.
